Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer.

Piccart, M J; Di Leo, A; Beauduin, M; Vindevoghel, A; Michel, J; Focan, C; Tagnon, A; Ries, F; Gobert, P; Finet, C; Closon-Dejardin, M T; Dufrane, J P; Kerger, J; Liebens, F; Beauvois, S; Bartholomeus, S; Dolci, S; Lobelle, J P; Paesmans, M; Nogaret, J M

Piccart, M J; Di Leo, A; Beauduin, M; Vindevoghel, A; Michel, J; Focan, C; Tagnon, A; Ries, F; Gobert, P; Finet, C; Closon-Dejardin, M T; Dufrane, J P; Kerger, J; Liebens, F; Beauvois, S; Bartholomeus, S; Dolci, S; Lobelle, J P; Paesmans, M; Nogaret, J M.

Affiliation

Piccart MJ; Jules Bordet Institute, Belgian and Luxembourg Cooperative Centers, and Pharmacia-Upjohn, Brussels, Belgium. martine.piccart@bordet.be

J Clin Oncol ; 19(12): 3103-10, 2001 Jun 15.

Article in En | MEDLINE | ID: mdl-11408507

Subject(s)

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols Type of study: Clinical_trials / Prognostic_studies Limits: Adult / Aged / Female / Humans / Middle aged Country/Region as subject: Europa Language: En Journal: J Clin Oncol Year: 2001 Document type: Article Affiliation country:

Search on Google

Add to My VHL

XML

PubMed Links